封面
市场调查报告书
商品编码
1411445

中轴型脊椎关节炎市场:按类型、按药物类别(抗风湿药、糖皮质激素、非类固醇消炎剂)、最终用户划分 - 2024-2030 年全球预测

Axial Spondyloarthritis Market by Type (Ankylosing Spondylitis, Non-Radiographic Axial Spondyloarthritis )), Drug Class (Anti-Rheumatic Drugs, Glucocorticoids, Non-steroidal anti-inflammatory Drugs ), End User - Global Forecast 2024-2030

出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

中轴型脊椎关节炎市场规模预估2023年为53.2亿美元,2024年达56.8亿美元,预计2030年将达87.9亿美元,复合年增长率为7.42%。

中轴型脊椎关节炎的全球市场

主要市场统计
基准年[2023] 53.2亿美元
预测年份 [2024] 56.8亿美元
预测年份 [2030] 87.9亿美元
复合年增长率(%) 7.42%
中轴型脊椎关节炎市场-IMG1

FPNV定位矩阵

FPNV定位矩阵对于评估中轴型脊椎关节炎市场至关重要。我们检视与业务策略和产品满意度相关的关键指标,以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出资讯的决策。根据评估,供应商被分为四个成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。

市场占有率分析

市场占有率分析是一种综合工具,可以对中轴型脊椎关节炎市场供应商的现状进行深入而详细的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献,以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外,该分析还提供了对该行业竞争特征的宝贵考察,包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更资讯的决策并制定有效的策略,从而在市场上获得竞争优势。

该报告对以下几个方面提供了宝贵的见解:

1-市场渗透率:提供有关主要企业所服务的市场的全面资讯。

2-市场开拓:我们深入研究利润丰厚的新兴市场,并分析它们在成熟细分市场中的渗透率。

3- 市场多元化:提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4-竞争力评估与资讯:对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。

5- 产品开发与创新:提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题:

一轴脊椎关节炎市场的市场规模与预测是多少?

在双轴脊椎关节炎市场的预测期内,有哪些产品、细分市场、应用和领域需要考虑投资?

3-中轴型脊椎关节炎市场的技术趋势和法律规范是什么?

4-4轴脊椎关节炎市场主要供应商的市场占有率是多少?

5-进入中轴型脊椎关节炎市场适当的型态和策略手段是什么?

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 关节炎和关节痛的发生率增加
      • 增加研发活动
      • 政府和私人公司努力扩大关节炎的治疗选择
    • 抑制因素
      • 产品和药品召回的发生率
    • 机会
      • 中轴型脊椎关节炎个体化照护的进展
      • 针对中轴型脊椎关节炎的新型生技药品的出现
    • 任务
      • 严格药品核准流程规定
  • 市场区隔分析
  • 市场趋势分析
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法律规范

第六章中轴型脊椎关节炎市场:依类型

  • 僵直性脊椎炎(AS)
  • 非 X 光中轴型脊椎关节炎 (nr-axSpA)

第七章中轴型脊椎关节炎市场:依药物类别

  • 抗风湿药
  • 糖皮质激素
  • 非类固醇消炎剂(NSAID)

第 8 章 中轴型脊椎关节炎市场:依最终使用者分类

  • 学术研究所
  • 诊所
  • 医院
  • 復健中心

第九章北美和南美中轴型脊椎关节炎市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第10章亚太地区中轴型脊椎关节炎市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲的中轴型脊椎关节炎市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争形势

  • FPNV定位矩阵
  • 市场占有率分析:主要企业
  • 主要企业竞争情境分析

第13章竞争产品组合

  • 主要公司简介
    • Abbott Laboratories
    • AbbVie Inc.
    • Amgen Inc.
    • Eli Lilly and Company
    • Galapagos NV
    • Inmagene Biopharmaceuticals
    • Johnson & Johnson Services, Inc.
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer Inc.
    • UCB SA
  • 主要产品系列

第十四章附录

  • 讨论指南
  • 关于许可证和定价
Product Code: MRR-5C6F41F5AF80

[180 Pages Report] The Axial Spondyloarthritis Market size was estimated at USD 5.32 billion in 2023 and expected to reach USD 5.68 billion in 2024, at a CAGR 7.42% to reach USD 8.79 billion by 2030.

Global Axial Spondyloarthritis Market

KEY MARKET STATISTICS
Base Year [2023] USD 5.32 billion
Estimated Year [2024] USD 5.68 billion
Forecast Year [2030] USD 8.79 billion
CAGR (%) 7.42%
Axial Spondyloarthritis Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Axial Spondyloarthritis Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Axial Spondyloarthritis Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Axial Spondyloarthritis Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Amgen Inc., Eli Lilly and Company, Galapagos NV, Inmagene Biopharmaceuticals, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., and UCB S.A..

Market Segmentation & Coverage

This research report categorizes the Axial Spondyloarthritis Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Ankylosing Spondylitis (AS)
    • Non-Radiographic Axial Spondyloarthritis (nr-axSpA))
  • Drug Class
    • Anti-Rheumatic Drugs
    • Glucocorticoids
    • Non-steroidal anti-inflammatory Drugs (NSAIDs)
  • End User
    • Academic Research Institutes
    • Clinics
    • Hospital
    • Rehabilitation Center
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Axial Spondyloarthritis Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Axial Spondyloarthritis Market?

3. What are the technology trends and regulatory frameworks in the Axial Spondyloarthritis Market?

4. What is the market share of the leading vendors in the Axial Spondyloarthritis Market?

5. Which modes and strategic moves are suitable for entering the Axial Spondyloarthritis Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Axial Spondyloarthritis Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of arthritis and joint pain
      • 5.1.1.2. Growing number of research and development activities
      • 5.1.1.3. Efforts by government and private players to expand treatment options for arthritis
    • 5.1.2. Restraints
      • 5.1.2.1. Incidences of product and drug recall
    • 5.1.3. Opportunities
      • 5.1.3.1. Advances in personalized care for axial spondyloarthritis
      • 5.1.3.2. Emergence of novel biologic agents targeting axial spondyloarthritis
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulations concerning the drug approval process
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Axial Spondyloarthritis Market, by Type

  • 6.1. Introduction
  • 6.2. Ankylosing Spondylitis (AS)
  • 6.3. Non-Radiographic Axial Spondyloarthritis (nr-axSpA))

7. Axial Spondyloarthritis Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Anti-Rheumatic Drugs
  • 7.3. Glucocorticoids
  • 7.4. Non-steroidal anti-inflammatory Drugs (NSAIDs)

8. Axial Spondyloarthritis Market, by End User

  • 8.1. Introduction
  • 8.2. Academic Research Institutes
  • 8.3. Clinics
  • 8.4. Hospital
  • 8.5. Rehabilitation Center

9. Americas Axial Spondyloarthritis Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Axial Spondyloarthritis Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Axial Spondyloarthritis Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. Abbott Laboratories
    • 13.1.2. AbbVie Inc.
    • 13.1.3. Amgen Inc.
    • 13.1.4. Eli Lilly and Company
    • 13.1.5. Galapagos NV
    • 13.1.6. Inmagene Biopharmaceuticals
    • 13.1.7. Johnson & Johnson Services, Inc.
    • 13.1.8. Merck & Co., Inc.
    • 13.1.9. Novartis AG
    • 13.1.10. Pfizer Inc.
    • 13.1.11. UCB S.A.
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. AXIAL SPONDYLOARTHRITIS MARKET RESEARCH PROCESS
  • FIGURE 2. AXIAL SPONDYLOARTHRITIS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. AXIAL SPONDYLOARTHRITIS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. AXIAL SPONDYLOARTHRITIS MARKET DYNAMICS
  • FIGURE 7. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 10. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 12. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. AXIAL SPONDYLOARTHRITIS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 22. AXIAL SPONDYLOARTHRITIS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. AXIAL SPONDYLOARTHRITIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. AXIAL SPONDYLOARTHRITIS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 6. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ANKYLOSING SPONDYLITIS (AS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (NR-AXSPA)), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 9. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ANTI-RHEUMATIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY GLUCOCORTICOIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 13. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY REHABILITATION CENTER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 44. CHINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 62. SINGAPORE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 65. SOUTH KOREA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. TAIWAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 71. THAILAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 74. VIETNAM AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 81. DENMARK AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. EGYPT AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 87. FINLAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. FRANCE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 93. GERMANY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 96. ISRAEL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 99. ITALY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. NETHERLANDS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 105. NIGERIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 108. NORWAY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 111. POLAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 114. QATAR AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 117. RUSSIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 120. SAUDI ARABIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 126. SPAIN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 129. SWEDEN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 132. SWITZERLAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 135. TURKEY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED ARAB EMIRATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 144. AXIAL SPONDYLOARTHRITIS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 145. AXIAL SPONDYLOARTHRITIS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 146. AXIAL SPONDYLOARTHRITIS MARKET LICENSE & PRICING